MediGene AG - Product Pipeline Review - 2016

  • ID: 3960476
  • Company Profile
  • 42 pages
  • Global Markets Direct
  • Medigene
1 of 5

FEATURED COMPANIES

  • Naia Limited
  • Shire Plc
  • Zealand Pharma A/S
  • MORE
MediGene AG - Product Pipeline Review - 2016

The report ‘MediGene AG - Product Pipeline Review - 2016’, provides an overview of the MediGene AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by MediGene AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of MediGene AG
- The report provides overview of MediGene AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses MediGene AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features MediGene AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate MediGene AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for MediGene AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding MediGene AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Naia Limited
  • Shire Plc
  • Zealand Pharma A/S
  • MORE
Introduction

MediGene AG Snapshot

MediGene AG Overview

Key Facts

MediGene AG - Research and Development Overview

Key Therapeutic Areas

MediGene AG - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

MediGene AG - Pipeline Products Glance

MediGene AG - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

MediGene AG - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

MediGene AG - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

MediGene AG - Unknown Stage Pipeline Products

Unknown Products/Combination Treatment Modalities

MediGene AG - Drug Profiles

Cellular Immunotherapy 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy 2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Acute Myeloblastic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target hTERT and Survivin for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target MAGE-A1 for Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target Opa-Interacting Protein 4 and Wilm's Tumor 1 for Acute Myeloblastic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 16, 31] (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target TCR for Autoimmune Disease and T-Cell Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RhuDex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sinecatechins - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MediGene AG - Pipeline Analysis

MediGene AG - Pipeline Products by Target

MediGene AG - Pipeline Products by Route of Administration

MediGene AG - Pipeline Products by Molecule Type

MediGene AG - Pipeline Products by Mechanism of Action

MediGene AG - Dormant Projects

MediGene AG - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

etomoxir

Monoclonal Antibody for Ovarian Cancer

MediGene AG - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

List of Tables

MediGene AG, Key Facts

MediGene AG - Pipeline by Indication, 2016

MediGene AG - Pipeline by Stage of Development, 2016

MediGene AG - Monotherapy Products in Pipeline, 2016

MediGene AG - Out-Licensed Products in Pipeline, 2016

MediGene AG - Out-Licensed Products/ Combination Treatment Modalities, 2016

MediGene AG - Phase III, 2016

MediGene AG - Phase II, 2016

MediGene AG - Phase I, 2016

MediGene AG - Preclinical, 2016

MediGene AG - Discovery, 2016

MediGene AG - Unknown, 2016

MediGene AG - Pipeline by Target, 2016

MediGene AG - Pipeline by Route of Administration, 2016

MediGene AG - Pipeline by Molecule Type, 2016

MediGene AG - Pipeline Products by Mechanism of Action, 2016

MediGene AG - Dormant Developmental Projects,2016

MediGene AG - Discontinued Pipeline Products, 2016

MediGene AG, Subsidiaries

List of Figures

MediGene AG - Pipeline by Top 10 Indication, 2016

MediGene AG - Pipeline by Stage of Development, 2016

MediGene AG - Monotherapy Products in Pipeline, 2016

MediGene AG - Out-Licensed Products in Pipeline, 2016

MediGene AG - Pipeline by Target, 2016

MediGene AG - Pipeline by Route of Administration, 2016

MediGene AG - Pipeline by Molecule Type, 2016

MediGene AG - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Naia Limited
- Shire Plc
- Tasly Pharmaceutical Group Co., Ltd.
- Zealand Pharma A/S
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll